Walter M. Stadler to Administration, Intravenous
This is a "connection" page, showing publications Walter M. Stadler has written about Administration, Intravenous.
Connection Strength
0.044
-
A randomized phase 2 network trial of tivantinib plus cetuximab versus cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma. Cancer. 2020 05 15; 126(10):2146-2152.
Score: 0.044